Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer… The main adverse events are neutropenia, fatigue and peripheral neuropathy.
Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles , Brussels , Belgium.
Laura
L
Polastro
Philippe G
PG
Aftimos
Ahmad
A
Awada
D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational; D004988:Ethers, Cyclic / Q000494:pharmacology; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005663:Furans / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018942:Macrolides / Q000494:pharmacology; D058990:Molecular Targeted Therapy; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy; D009503:Neutropenia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D050257:Tubulin Modulators / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004988:Ethers, Cyclic; D005663:Furans; D007659:Ketones; D018942:Macrolides; D050257:Tubulin Modulators; C070519:halichondrin B; D000095662:Polyether Polyketides; C490954:eribulin
breast cancer; chemotherapy; eribulin; review; solid tumor